Suzanne Ildstad - Feb 1, 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TALS)

Role: Chief Scientific Officer
Signature: /s/ Mary Kay Fenton, attorney-in-fact
Stock symbol: TALS
Transactions as of: Feb 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/2/2022, 05:04 PM
Next filing: Aug 23, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TALS	Common Stock	Gift	$0	-1.2M	-24.97%	$0.00	3.61M	Nov 17, 2021	Direct	F1
transaction	TALS	Common Stock	Gift	$0	+1.2M		$0.00	1.2M	Nov 17, 2021	By GRAT	F1
holding	TALS	Common Stock						654K	Feb 1, 2022	See Footnote	F2
holding	TALS	Common Stock						654K	Feb 1, 2022	See Footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TALS	Stock Option (Right to Buy)	Award	$0	+150K		$0.00	150K	Feb 1, 2022	Common Stock	150K	$9.10	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents transfer of shares to the Reporting Person's GRAT.
F2	These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Persons son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3	These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Persons daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4	The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter.